Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Capital Employed: 2018-2025

Historic Return on Capital Employed for Protagonist Therapeutics (PTGX) over the last 8 years, with Sep 2025 value amounting to 0.03%.

  • Protagonist Therapeutics' Return on Capital Employed fell 24.00% to 0.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.03%, marking a year-over-year decrease of 24.00%. This contributed to the annual value of 0.50% for FY2024, which is 83.00% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' Return on Capital Employed stood at 0.03%, which was down 17.18% from 0.03% recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Return on Capital Employed peaked at 0.40% during Q4 2024, and registered a low of -0.66% during Q1 2023.
  • In the last 3 years, Protagonist Therapeutics' Return on Capital Employed had a median value of 0.03% in 2025 and averaged -0.06%.
  • As far as peak fluctuations go, Protagonist Therapeutics' Return on Capital Employed surged by 99bps in 2024, and later declined by 29bps in 2025.
  • Protagonist Therapeutics' Return on Capital Employed (Quarterly) stood at -0.40% in 2021, then decreased by 16bps to -0.56% in 2022, then climbed by 27bps to -0.29% in 2023, then skyrocketed by 69bps to 0.40% in 2024, then declined by 24bps to 0.03% in 2025.
  • Its Return on Capital Employed stands at 0.03% for Q3 2025, versus 0.03% for Q2 2025 and 0.04% for Q1 2025.